Research programme: immunostimulatory peptides - SIDR

Drug Profile

Research programme: immunostimulatory peptides - SIDR

Alternative Names: Immunostimulatory peptides research programme - Strathclyde Institute for Drug Research; Immunostimulatory peptides research programme- SIDR; Research programme: immunostimulatory peptides - Strathclyde Institute for Drug Research

Latest Information Update: 27 Apr 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Strathclyde Institute for Drug Research
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Immunodeficiency disorders

Most Recent Events

  • 27 Apr 2001 Discontinued-Preclinical for Immunodeficiency disorders in United Kingdom (Unknown route)
  • 01 Nov 1999 This programme is available for licensing (http://www.sidr.org)
  • 20 Jul 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top